Advertise on podcast: Pharma Minds

Et si standardiser les flux de patients permettait de mieux les soigner ? Dans cet épisode de Pharma minds, je reçois Loïc Lagarde, directeur général de la Clinique Pasteur à Toulouse. Ingénieur de formation, passé par Google, YouTube et l’entrepreneuriat avec Santé Discount, il apporte un regard différent sur l’organisation des établissements de santé. À la Clinique Pasteur, ce regard se traduit par une conviction forte : pour mieux personnaliser les soins, il faut d’abord savoir standardiser ce qui peut l’être. Au programme de cet épisode : ◾️ Un modèle économique atypique : pourquoi la Clinique Pasteur réinvestit ses résultats depuis 70 ans et comment cette indépendance favorise l’investissement et la prise de risque. ◾️ Le patient comme un flux : comment organiser les parcours selon leur vitesse et leurs besoins, plutôt que de faire passer tout le monde par les mêmes circuits. ◾️ La standardisation au service de l’humain : pourquoi regrouper les prises en charge qui se ressemblent permet de libérer du temps soignant et de mieux personnaliser les autres. ◾️ L’innovation concrète à l’hôpital : robotisation de la pharmacie à usage intérieur, optimisation de la logistique et développement de l’hospitalisation à domicile. ◾️ De nouveaux rôles dans le soin : ce que l’expérimentation autour des maladies chroniques révèle sur l’accompagnement et la motivation des patients. ◾️ Conduite du changement et management : comment faire évoluer les pratiques, dépasser les résistances et pourquoi les ressources humaines sont aussi l’affaire des dirigeants. ◾️ Digitalisation et intelligence artificielle : quelle place donner à la technologie dans un système où le temps humain reste essentiel. Derrière ces projets, un objectif guide, selon Loïc Lagarde, 95 % de ses décisions : libérer du temps soignant. Une conversation sur ce que l’ingénierie et une autre approche du management peuvent apporter à la santé, sans perdre de vue l’essentiel : le patient et la relation de soin. Merci à notre partenaire BD France pour son soutien dans cet épisode, qui nous permet d’ouvrir le dialogue autour de l’innovation et des enjeux de santé. La ligne éditoriale reste entre nos mains. Pour retrouver Loïc Lagarde : LinkedIn : https://www.linkedin.com/in/llagarde/ La Clinique Pasteur : https://www.clinique-pasteur.com/ Ressources mentionnées : 📌 Santé Discount (devenue Atida maintenant) : https://www.atida.fr/ 📌 L'expérimentation Constel'Action : un dispositif autour de l’accompagnement des personnes atteintes de maladies chroniques et de leur parcours de soins. -- 🤝 Retrouvez-moi sur LinkedIn. 📩 Abonnez-vous à la newsletter Pharma Minds. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Comment faire accepter le changement sans que les équipes aient le sentiment que leur travail passé est remis en question ? Pour Loïc Lagarde, dirigeant de la Clinique Pasteur à Toulouse, changer ne signifie pas que ce qu’on faisait avant était mauvais. Cela signifie que nos pratiques doivent évoluer pour s’adapter à la réalité d’aujourd’hui. Mais avant de transformer quoi que ce soit, il faut accepter de regarder les choses telles qu’elles sont. Et c’est aussi le rôle d’un dirigeant : porter un miroir, plutôt que chercher des coupables. Rendez-vous demain pour découvrir l'épisode complet ! Et pour les plus curieux, voici un sneak peek de ce que vous allez découvrir : ◾️ Un modèle économique atypique : pourquoi la Clinique Pasteur réinvestit ses résultats depuis 70 ans et comment cette indépendance favorise l’investissement et la prise de risque. ◾️ Le patient comme un flux : comment organiser les parcours selon leur vitesse et leurs besoins, plutôt que de faire passer tout le monde par les mêmes circuits. ◾️ La standardisation au service de l’humain : pourquoi regrouper les prises en charge qui se ressemblent permet de libérer du temps soignant et de mieux personnaliser les autres. ◾️ L’innovation concrète à l’hôpital : robotisation de la pharmacie à usage intérieur, optimisation de la logistique et développement de l’hospitalisation à domicile. ◾️ De nouveaux rôles dans le soin : ce que l’expérimentation autour des maladies chroniques révèle sur l’accompagnement et la motivation des patients. ◾️ Conduite du changement et management : comment faire évoluer les pratiques, dépasser les résistances et pourquoi les ressources humaines sont aussi l’affaire des dirigeants. ◾️ Digitalisation et intelligence artificielle : quelle place donner à la technologie dans un système où le temps humain reste essentiel. __ 📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds. 🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies in Vienna. After five episodes looking at Europe’s access dilemma from the perspective of industry, research and consulting, this conversation brings in a very different voice: someone who advises policymakers and public payers. We start with a fundamental question: what does access actually mean? Regulatory approval is only the beginning. A medicine also needs to be available and affordable. From there, Sabine challenges some of the assumptions behind the current debate around pharma innovation, drug pricing and access in Europe: ◾️ Why a new medicine is not necessarily an innovative one ◾️ What evidence should really justify a higher price ◾️ Whether Europe could ever move towards a more coordinated pricing model ◾️ What confidential discounts mean for public payers ◾️ And whether industrial policy and innovation should really be financed through medicine prices She also explains why horizon scanning could help European payers prepare much earlier for the medicines coming through the pipeline. A bonus episode that doesn't necessarily give the same answers as the rest of the series — but asks some uncomfortable questions about what Europe is actually paying for, and how we define innovation in the first place. 👉To find Sabine Vogler: https://www.linkedin.com/in/sabine-vogler-8ba943254/Resources mentioned in the episode: 📌 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (GÖG, PPRI): https://ppri.goeg.at/whocc📌 Study on enhanced cross-country coordination in the area of pharmaceutical product pricing (European Commission, 2016): https://health.ec.europa.eu/latest-updates/study-enhanced-cross-country-coordination-area-pharmaceutical-product-pricing-2016-02-24_en📌 Davis et al., BMJ 2017, cancer drugs approved by the EMA without clear evidence of survival or quality-of-life benefit: https://www.bmj.com/lookup/doi/10.1136/bmj.j4530📌 International Horizon Scanning Initiative (IHSI): https://ncpe.ie/international-collaborations/international-horizon-scanning-initiative/📌 Also cited: BeNeLuxA, the Nordic Pharmaceutical Forum, the European HTA regulation and its joint clinical assessments (JCA) ___ 📩 Subscribe to the newsletter: https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait longer. Or change the model. Europe wants three things at once: medicines people can afford, fast access to new drugs, and a strong pharma industry. Is that still possible? My guest is Graham Cookson, Chief Executive of the Office of Health Economics (OHE) in London. He is an econometrician who works on healthcare efficiency, drug pricing and reimbursement. He starts with Germany, the country at the center of MFN. What you will learn in this episode: Germany's trilemma: a big buyer with a budget hole, a big producer of innovation, and a big exporter to the US. That is why it has "a target on its back".The MFN paradox: why MFN should push US prices down, and why it is really about US revenues.Something has to give: low prices, the latest drugs and more investment are not compatible in the short run.The UK deal: paying more for medicines in exchange for tariff relief and investment.No single European price: what a "NATO-style" agreement could look like instead.The hidden trade-offs: why the worst outcome is letting America decide what Europe pays.Health as an investment: why Europe can act as 27 nations, or as one bloc. Listen to this episode for a European economist's view of pharma's big picture today: which ways out Europe still has, and what each one will cost. Ressources: 📌 "FOIA Documents: Trump-Pharma MFN Drug Pricing Deals": https://www.citizen.org/article/foia-documents-trump-pharma-mfn-drug-pricing-deals/ 📌 Office of Health Economics (OHE): https://www.ohe.org 📖 Read Graham's article: Germany's drug-pricing dilemma: Why Europe's pivotal market holds the key to the MFN debate (OHE, June 2026)https://www.ohe.org/insights/germanys-drug-pricing-dilemma-why-europes-pivotal-market-holds-the-key-to-the-mfn-debate/ ___ 📩 Subscribe to the newsletter: https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three? In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation. Science is moving faster. Competition is accelerating. And at the same time, MFN pricing, healthcare budget pressures and increasingly complex market access are challenging the traditional model on both sides of the Atlantic. An innovative treatment could once expect five to eight years before serious competition entered the same space. Today, Marine argues, that window can be closer to two or three years, even while the original molecule remains protected.  So what happens when the time available to capture the value of innovation gets shorter? We explore: ◾️ Why the next wave of pharma innovation is structurally different ◾️ What MFN reveals about the limits of today’s pricing model ◾️ Why demonstrating patient value earlier is becoming critical ◾️ What is really slowing market access in Europe ◾️ Why being first to market may no longer be enough ◾️ And what a more sustainable model for pharma, payers and patients could look like Marine’s perspective reframes MFN not simply as a threat, but as a signal that the rules of pharmaceutical innovation are changing. This is episode #4 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. To find Marine Baxendell:  LinkedIn: https://www.linkedin.com/in/marine-baxendell/ Resources mentioned in the episode: 📌 xcube.bio : https://xcube.bio/ ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders start adapting their commercial strategies to the new Most Favored Nation (MFN) environment. And one thing is clear:uncertainty is here to stay. From early-stage assets to upcoming launches and portfolio decisions, MFN is forcing companies to rethink the traditional launch playbook. US and European pricing have always been interconnected, but those links now need to be considered much more intentionally, and much earlier, from Phase I or II of development. Launch sequencing is becoming more complex, requiring teams to anticipate the impact across markets from the very beginning. We explore: ◾️ Why MFN has become a top-of-mind issue for pharma leaders ◾️ How MFN is already changing global launch sequencing ◾️ Why even rare disease and early-stage assets may need to prepare ◾️ How scenario planning can help teams navigate regulatory and pricing uncertainty ◾️ Why commercial, market access, medical and other functions need to work together much earlier ◾️ How pharma companies can build more flexible go-to-market models ◾️ When it may make sense to deprioritize an indication, market or investment ◾️ What delayed launches could ultimately mean for patient access to innovation ◾️ And why “wait and see” may be one of the riskiest strategies of all The companies best prepared for what comes next will not necessarily be those that correctly predict exactly how MFN will unfold. They will be those that build different scenarios, preserve optionality, connect decisions across their portfolio and prepare their teams early. Because under MFN, the old launch playbook may not be enough. This is episode #3 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. To find Laure Nas de Tourris: LinkedIn: https://www.linkedin.com/in/laurenasdetourris/ MFN as a Catalyst for Strategic Reinvention https://clarivate.com/life-sciences-healthcare/wp-content/uploads/sites/4/dlm_uploads/2026/09/MFN-as-Catalyst-for-Reinvention-Clarivate.pdf___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma ecosystem. Franck spent 20 years in China as a Senior Partner at McKinsey, advising some of the world’s largest pharmaceutical companies as China transformed from a market for Western medicines into a global source of biopharma innovation. Today, he is working on building bridges between Western innovation and Asian capabilities. That transformation is at the heart of our conversation.  Because Europe faces an uncomfortable equation. The pharmaceutical industry has become increasingly US-centric. The majority of its profits are generated in the US, investment has followed, and Europe has progressively lost influence. At the same time, European governments face growing fiscal constraints, making simply spending more on innovative medicines increasingly difficult.  Franck makes the case for another path: co-development with Asia. We explore: ◾️ How China became one of the world’s leading biopharma innovation ecosystems ◾️ Why US pharma is moving faster than Europe to tap into Chinese biotech innovation ◾️ How Asia could help reduce the cost and accelerate the execution of clinical trials and drug development ◾️ Why Europe can no longer afford to look at China only as a competitive threat ◾️ What Europe–Asia co-development could look like in practice ◾️ How Europe could combine Asian capabilities with its own strengths in research, development and manufacturing ◾️ And whether this model could help Europe regain pharmaceutical competitiveness while protecting its sovereignty Franck’s argument is not that Europe should replace its relationship with the US with China. It is that Europe needs to engage with Asia strategically, learn from ecosystems that move faster, and build new forms of collaboration that preserve European strengths and sovereignty. Ultimately, making pharmaceutical innovation accessible to more patients will require more than higher budgets. It means bringing R&D and manufacturing costs down, rethinking pricing, and creating ecosystems that know how to collaborate and compete. This is episode #2 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. Franck Le Deu: https://www.linkedin.com/in/franck-le-deu/ Resources mentioned in the episode: 📌 PhRMA Forum 2026 - “China’s Leading Edge: What’s at Risk” : https://www.innovation.org/phrma-forum/ 📌 “Europe’s narrow path between the U.S. and China in biotech”, an article from Franck Le Deu, BioCentury : https://www.biocentury.com/article/659819/ Further reading from Franck Le Deu: 📌 “In support of a multipolar biopharma world: Guest Commentary", BioCentury : https://www.biocentury.com/article/658573 ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens when the rules of global drug pricing change? Trump’s Most Favored Nation (MFN) policy is putting pressure on pharmaceutical prices in the US. But the consequences may extend far beyond American patients, and Europe may end up paying part of the price. Christoffer explains what he is hearing from industry and policy experts, and why delayed launches and higher prices in Europe may not be temporary effects. In some European countries, fewer new medicines are already being launched, raising a fundamental question about access to innovation. We also explore: ◾️ Why Europe is struggling to speak with one voice on pharmaceutical pricing and market access ◾️ Whether national pricing and reimbursement systems are still sustainable ◾️ Whether a more coordinated European pricing and reimbursement system could improve access ◾️ Why the EU’s Biotech Act may not be enough to make Europe attractive for pharmaceutical R&D and manufacturing ◾️ And why the consequences of MFN could be much more permanent than a Trump presidency.  This is not simply a story about Trump or pricing. It is a conversation about Europe’s pharmaceutical competitiveness, access to innovation, and the choices Europe will have to make if it wants to remain an attractive market for the medicines of tomorrow. To find Christoffer Frendesen: LinkedIn Resources mentioned in the episode: 📌 Trump’s Most Favored Nation (MFN) policy: https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/ 📌 The EU Critical Medicines Act: https://health.ec.europa.eu/medicinal-products/critical-medicines-act_en 📌 The EU Biotech Act: https://health.ec.europa.eu/biotechnology/european-biotech-act_en 📌 GlobalData - March 2026https://www.pharmaceutical-technology.com/analyst-comment/most-favored-nation-policy-early-insights-into-europe-response/📌 IQVIA - July 2026https://www.iqvia.com/locations/emea/blogs/2026/07/tracking-mfns-impact-on-innovative-medicine-launches ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Compléments alimentaires, cosmétiques, huiles essentielles, biocides, laits infantiles... Certains produits se situent à la frontière de plusieurs catégories réglementaires. Et selon leur composition, leur destination ou leur présentation, leur statut peut changer. Dans cet épisode de Pharma Minds Insights, je reçois Béatrice Espesson-Vergeat, spécialisée en droit pharmaceutique et réglementaire au cabinet BCTG Avocats, pour comprendre pourquoi les produits frontières sont bien plus qu'un sujet de conformité. Car une requalification réglementaire peut avoir des conséquences très concrètes sur la distribution, le développement ou même l'avenir d'un produit. L'exemple du peroxyde d'hydrogène montre notamment à quel point une évolution réglementaire peut contraindre certaines entreprises à retirer leurs produits ou à revoir complètement leur activité.  Mais faut-il pour autant subir la réglementation ? Dans cet échange, nous explorons une autre approche : anticiper les évolutions réglementaires, évaluer les risques et construire une stratégie produit en transversalité avec les équipes réglementaires, juridiques et marketing. Vous découvrirez : ◾️ Pourquoi le positionnement réglementaire d'un produit peut devenir un véritable choix stratégique ; ◾️ Comment arbitrer entre enjeux sanitaires et économiques ; ◾️ Pourquoi certaines évolutions réglementaires peuvent être anticipées ; ◾️ Et comment transformer une mise en conformité anticipée en avantage concurrentiel.  Bonne écoute ! -- Merci à notre partenaire BCTG Avocats d’avoir rendu cet épisode possible et de nous aider à comprendre les tendances de fond dans la régulation du secteur. Comme toujours, l’équipe Pharma Minds garde la main sur la ligne éditoriale et le choix des invités. Pour retrouver BCTG Avocats : 📌 Site internet BCTG Avocats : https://bctg-avocats.com 📌 Pour contacter BCTG Avocats : https://bctg-avocats.com/nous-contacter/ 📌 LinkedIn : https://www.linkedin.com/company/bctg-avocats/ Ressources mentionnées dans l’épisode : 📌 Arrêt de justice concernant le peroxyde d'hydrogène : https://eur-lex.europa.eu/legal-content/FR/ALL/?uri=ecli:ECLI:EU:C:2015:335 -- 🎧 Vous êtes nouveau par ici ? Pour comprendre en un clin d'œil le panorama des épisodes, téléchargez « 25 conseils pour un leadership engagé », un guide inspiré des meilleurs conseils de mes invités. 🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn. 📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Organizations demand infinite growth in finite markets. Leaders are left at the crossroads of irreconcilable missions, balancing economic imperatives with the well-being of their teams. What happens when the equation simply has no solution? The cost of execution is sometimes your own breaking point. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". For this final episode of our miniseries, I wanted to explore what execution reveals about oneself at the deepest level. I chose to speak with Patrice because his journey shows what it concretely costs to actually do what you said you would do. Execution eventually ceases to be a professional requirement. It becomes a personal decision to put skin in the game, without a safety net, but with singular intention.  Patrice Zagame is the Founder and CEO of Eolias Health, an OTC lab for plant-based products aimed at the Brazilian market. After spending 35 years in the pharmaceutical industry and managing global subsidiaries for 16 years, he knows the weight of impossible contexts. From handling severe price cuts and sales force reductions in France to surviving executive burnout and ultimately funding his own venture, Patrice embodies the courage of leaving the comfort of a massive organization to truly walk the talk. In this episode, we cover: ◾️The Impossible Equation : Balancing double-digit growth demands with saturated markets and massive price cuts. ◾️Choice Versus Chance : Why letting an organization dictate your pace can cost you the most crucial turns in your career. ◾️The Silent Break : Recognizing the boiling point of executive burnout and walking away to change the equation. ◾️Managing the Smartest Room : Stepping back from ego to lead experts who know more than you do. ◾️Walking the Talk : Leaving corporate security to fund an entrepreneurial venture from scratch. Commitment is not a corporate posture. It is a daily decision renewed in the face of impossible contexts. At some point, managing the system is no longer enough.  👉 What is the hardest career pivot you have had to make to protect your own values? Let us know in the comments. Strategies demand growth. Reality demands resilience. If you want to follow the whole series, don't forget to subscribe. - This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series.   Originally released on: 30/05/2023. To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/patrice-zagame-senior-executive-ceo-fondateur-eolias-health-vibrer-avec-des-equipes-de-20-200-2000-personnes. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

You can have the best science in the world, but it means nothing if your company runs out of cash. When resources are limited and markets are unforgiving, execution ceases to be a management theory. It becomes a strict matter of survival. What does it actually cost to fund biotech innovation without losing control of your clinical vision?  Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I wanted to place this conversation fourth in this miniseries because it captures the absolute moment of truth in execution. When science is not enough and resources are scarce, every decision can dictate whether a company lives or dies. In early-stage biotech, executing is deeply radical. It is about choosing, accepting what you will not do, and holding that line. After looking at markets and systems in earlier episodes, we have reached the barest level of execution: two leaders, pure science, and the cold reality of how we fund what we believe in. In this episode, I sit down with Marc de Garidel, CEO of Abivax, and Paul Bravetti, CEO of Brenus Pharma. From late-stage clinical phase trials to highly complex first-in-human oncology immunotherapies, they share their impossible context: navigating environments where capital is tight, valuation paradigms have shifted, and strict focus is the only strategy that works. They break down what it takes to execute safely and scale disruptive science. In this episode, we cover: ◾️The Survival Discipline : Why execution in biotech means ruthless prioritization and strict cost control. ◾️Valuing Innovation : Anticipating regulatory milestones and de-risking science early to attract investors. ◾️The Manufacturing Trap : How Chemistry, Manufacturing, and Controls (CMC) can make or break a clinical asset. ◾️Financing Strategy : Timing your private rounds, handling market downturns, and the leap to the Nasdaq. ◾️The Exit Illusion : Why building a company just to sell it is a mistake, and how developing a great drug attracts buyers naturally. The rules of biotech are stark. Focus creates value. Distraction destroys it. You protect the science by making hard decisions early. 👉 What is the hardest trade-off you have had to make when allocating resources to a new project? Let us know in the comments. Science starts the journey. Execution secures the funding.  If you want to follow the whole series, don't forget to subscribe. - This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series.  Originally released on: 26/01/2026. To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/50-batir-une-biotech-a-succes-decisions-cles-arbitrages-et-erreurs-a-eviter-table-ronde-avec-marc-de-garidel-paul. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What do we do when the ground is unstable and information is incomplete? We are told to wait for the right conditions. But what if waiting costs more than acting? The real risk is failing to achieve your purpose. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I chose this specific conversation because Marc is the one who speaks best about what execution requires when the context refuses to stabilize. Through his experience, I wanted to explore what it concretely costs to actually do what you said you would do. His answer is very simple: we trust the ground and move forward. It reveals that accepting certain departures, stopping certain projects, and changing directions are the necessary costs of executing with integrity.  Marc Gailhardou (who has since been appointed President Intercontinental Region at MSD) brings this perspective from his role leading the EEMEA zone for MSD, while also serving on the board of the digital health startup The Resilience in Oncology. Tasked with managing a geographical area consisting of 25 percent of the world's population, his impossible context is one of permanent volatility. From maintaining operations across war zones to meeting the demands of emerging economies, he proves that long-term vision requires immediate, bold action.  In this episode, we cover: ◾️Leading Through Volatility : Managing safety, compliance, and operations across the diverse EEMEA region. ◾️The Appetite for the Future : Why high-growth markets embrace bold strategies while mature markets hesitate. ◾️Career as a Marathon : Moving out of your comfort zone, creating options, and knowing when it is time to transition. ◾️Corporate to Startup : Gaining agility, speed, and new perspectives through board roles at organizations like The Resilience in Oncology. ◾️Clarity Over Brutality : Focusing on the task rather than attacking the person to lead with respect. Execution without stability is rarely comfortable. It demands hard choices and decisive momentum. Clarity wins over caution every time. 👉 How do you balance the need to act with the pressure to wait for better data? Let us know in the comments.Science creates hope. Reality decides impact. If you want to follow the whole series, don't forget to subscribe. - This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series. Originally released on: 15/12/2025. To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/48-why-avoiding-risk-is-the-biggest-threat-to-your-pharma-career. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

A third of tomorrow's molecules will come from China. Just ten years ago, that figure was three percent. The entire healthcare ecosystem has shifted from a massive potential market into a testing ground for rapid, decentralized execution.The questions goes beyond how to enter this system, but how to keep pace with its relentless evolution. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I placed this conversation with Guillaume Delmotte in the second position of our series because he brings something the other episodes simply do not have: a systemic reading of execution. In China, execution is not an individual choice but a mode of operation for the state, highly centralized in its objectives and completely decentralized in its application. I chose this discussion to explore what it concretely costs to actually do what you said you would do at a massive, systemic scale. It reveals that large-scale delivery is only possible when partnerships are built for the long term and when you accept that constant adaptation becomes the course itself.  Guillaume Delmotte spent twenty years within Ipsen, navigating international leadership roles across Europe, Russia, and most recently China. Operating in a highly fluid, fiercely competitive market of 1.4 billion people, his impossible context was learning to execute without a rigid playbook. He had to navigate the immense tension between capturing an unprecedented volume opportunity and facing brutal price pressures, all while reinventing patient pathways from the ground up alongside local players. In this episode, we cover: ◾️Geography Commands Strategy : Why adapting tactics to localized provincial health policies is the only way to scale. ◾️The Virtual Hospital Shift : How digitized care pathways and AI are managing patient flows for minor and severe pathologies. ◾️Breaking the Pricing Rules : Moving away from rigid formulation constraints to establish entirely new value models. ◾️Building True Ecosystems : Leveraging local distributors and pharmacy data mining to find undiagnosed rare disease patients. ◾️The Innovation Mirage : Balancing incredible volume potential with aggressive price cuts and volume-based procurement. The final objective remains clear. The path to get there changes every single day. Those who stop moving lose the market.  👉 What element of the Chinese execution model do you think European pharma should adopt first? Let us know in the comments.  Ambition sets the target. Local context dictates the path. If you want to follow the whole series, don't forget to subscribe. - This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series.  Originally released on: 12/01/2026. To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/49-du-chaos-au-futur-les-lecons-d-un-leader-pharma-en-chine. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What does it truly take to stick to a difficult plan when absolutely no one around you can yet see the necessity to hold on? True transformation in healthcare is rarely a quick pivot sparked by a dramatic event. It is a slow, methodical rebuild from the ground up. The stakes are profound: evolving from a simple reference tool to a medical device where a single algorithmic error can cost a life. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I wanted to start this series with Vincent Bouvier because his journey illustrates something fundamental and deeply misunderstood about execution. Execution is not a question of speed, but a question of duration. He shows us what it actually costs to do what you said you would do over the long run, maintaining a good direction with the right funding, the right shareholder, and the discipline to invest at the exact right moment. Vincent Bouvier, Head of Vidal, stepped into a traditional publishing house famous for its red dictionary, with revenue entirely funded by the pharmaceutical industry. His impossible context was seeing the absolute necessity of structuring clinical data into software long before the market demanded it. Tied strictly to our season theme, his story proves that executing differently requires the courage to make calm, hard decisions and hold them steady across two decades of technological and financial upheaval. In this episode, we cover: ◾️ The Business Pivot : Shifting revenue from pharma-funded monographs to subscription-based clinical software for professionals. ◾️ The Integration Strategy : Embedding complex pharmacological knowledge directly into electronic medical records across local markets. ◾️ The Shareholder Equation : Trading short-term investment funds for a long-term Japanese industrial partner to secure the vision. ◾️ The Medical Device Standard : Treating software precision with the exact same rigor as manufacturing a pacemaker. ◾️ The Next Frontier : Leveraging generative AI to process vast patient histories and refine medical suggestions globally. Execution is not a sprint. It is a refusal to let short-term pressure dictate the roadmap. Three pillars: conviction, aligned capital, and timely investment. 👉 How do you protect your long-term strategic plans against short-term financial pressures? Let us know in the comments. Vision sets the bearing. Time decides the impact. If you want to follow the whole series, don't forget to subscribe.- This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series. Originally released on: 04/11/2024. To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/vidal-du-livre-rouge-a-l-outil-incontournable-d-aide-a-la-decision-medicale-vincent-bouvier-ceo-vidal-group. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Les groupements de pharmacies sont dans le viseur des pouvoirs publics (et ce n'est que le début). Dans ce nouvel épisode de Pharma Minds Insights, je reçois Hugues Villey Desmeserets, avocat associé chez BCTG Avocats et expert de la distribution pharmaceutique. Il est déjà venu à ce micro l'année dernière pour décrypter pourquoi les groupements de pharmacies étaient dans le viseur des députés, il revient aujourd'hui avec un œil nouveau, après la publication d'un rapport IGF-IGAS qui regarde de près l'ensemble de la chaîne de distribution pharmaceutique. Ce rapport met en lumière une réalité que peu d'acteurs voulaient regarder en face : des opérateurs non prévus par le Code de la santé publique, transitant des flux financiers considérables, sans cadre de transparence ni obligation de justifier leur valeur ajoutée. Avec Hugues, on décrypte ce que ce rapport change concrètement pour chaque maillon de la chaîne : groupements, pharmaciens officinaux et laboratoires pharmaceutiques. Dans cet épisode, vous découvrirez : ◾️ Pourquoi le rapport IGF-IGAS reconnaît implicitement la légitimité des groupements de pharmacie, tout en questionnant sévèrement leur valeur ajoutée ◾️ Ce que la transparence financière sur les flux entre laboratoires, groupements et officines implique concrètement pour chaque acteur ◾️ Pourquoi une transparence absolue pourrait paradoxalement détruire la dynamique concurrentielle  ◾️ Comment les deux métiers du pharmacien redéfinissent la place des groupements ◾️ Pourquoi l'indépendance du pharmacien reste un principe juridique non négociable, et ce que ça implique pour les contrats avec les groupements ◾️ Les contrôles qui s'annoncent, et pourquoi les laboratoires ne peuvent pas se permettre d'attendre pour se préparer ◾️ La question que chaque laboratoire doit se poser dès maintenant sur la visibilité de ses flux financiers Si vous évoluez dans l'écosystème pharmaceutique (que vous soyez laboratoire, groupement ou pharmacien) cet épisode vous donne les clés pour comprendre ce qui se dessine et anticiper les prochaines étapes. -- Merci à notre partenaire BCTG Avocats d’avoir rendu cet épisode possible et de nous aider à comprendre les tendances de fond dans la régulation du secteur. Comme toujours, l’équipe Pharma Minds garde la main sur la ligne éditoriale et le choix des invités. Pour retrouver le cabinet BCTG Avocats : 📌 Site internet : https://bctg-avocats.com 📌 Pour les contacter : https://bctg-avocats.com/nous-contacter/ 📌 LinkedIn : https://www.linkedin.com/company/bctg-avocats/ Ressources mentionnées dans l’épisode : 🎧 Épisode “Groupements de pharmacies : pourquoi un amendement visait à les interdire ?” : https://smartlink.ausha.co/pharma-minds/insights-groupements-de-pharmacies-pourquoi-un-amendement-visait-a-les-interdire 📌 Le rapport IGAS et IGF - mai 2026 : https://www.igas.gouv.fr/la-chaine-de-distribution-pharmaceutique Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.